Genome-editing technology has broad potential for treating cancers
the ONA take:
Researchers from the Walter and Eliza Hall Institute, in Melbourne, Australia, have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Using the technology, called CRISPR, the researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
The technology can directly target any gene in a person’s genome, thereby overcoming many problems commonly encountered in drug development.
The system works by efficiently locating and targeting a particular gene. It can introduce mutations that make the genome nonfunctional, or introduce changes that make mutated genes function normally again.
The researchers report that the technology has a wide range of potential in terms of drug development for treating genetic diseases such as cancer.
Researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|